Andere talen Acurx Pharmaceuticals, Inc.

Aandelen

ACXP

US00510M1045

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 07-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,97 ^USD	-5,29%		-10,45%	-48,56%

02/05	Acurx Pharmaceuticals, Inc. kondigt de presentatie aan van de resultaten van de Fase 2 klinische studie met ibezapolstat tijdens de ESCMID wereldwijde wetenschappelijke conferentie	CI
04/04	Top premarket stijgers	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference	02/05
Acurx Pharmaceuticals, Inc. Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global Scientific Conference	02/05
Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference	25/04
Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update	23/04
Top Premarket Gainers	04/04
Acurx Pharmaceuticals, Inc. Announces Participation in the LD Micro Invitational XIV	21/03
Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	19/03
US Futures Trend Lower in Tuesday's Premarket as Investors Await Start of 2-Day Fed Meeting	19/03
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update	18/03
Acurx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/03
Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update	04/03
New to the Street TV Series on Bloomberg and Fox Business, Innovative Companies Spotlighted: ACXP, TNXP, PETV, SWISF, GEVI, CLNV	01/03
Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development	27/02
Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients	29/01
Acurx Pharmaceuticals, Inc. Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2B Clinical Trial in Cdi Patients	29/01
Acurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024, February 1, 2024	24/01
Acurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024	23/01
Acurx Pharmaceuticals' Phase 2b Results For Ibezapolstat Bests Standard Of Care Vancomycin To Treat C. Difficile ($ACXP)	22/01
Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients	17/01
Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2B Clinical Trial in CDI Patients	17/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Acurx Pharmaceuticals, Inc.

Aandelen

ACXP

US00510M1045

Andere talen

Filters